Renephra Limited

Life Sciences
Medical Technology
Aim of funding: 
HMRC Advance Assurance received: 

Renephra Limited


Renephra Ltd is a UK based medical device development company that has developed and patented a disruptive technology that addresses the significant ongoing medical problems associated with treatment resistance of fluid overload within the body. Health issues often associated with fluid retention include heart failure and chronic oedema / lymphoedema in vascular, oncology alongside other impacting and personally debilitating diseases.

Renephra’s medical device removes excess fluid from the body by removing it from the skin. It uses microneedles to access fluid located in epidermis/dermis and negative pressure to remove it.

A recent 84 patient study at the Central Manchester NHS Foundation Trust has demonstrated that the excess fluid is accessible once the stratum corneum is breached. Renephra will be the first medical company to use negative pressure to extract excess fluid via its patented device and know how.


The product has two main drivers which the company believes makes its product uniquely positioned in what is a very competitive market space;

  • The product has the potential to vastly reduce the time (in days) a patient spends in hospital with fluid retention health problems thereby saving the NHS potentially millions of pound annually.
  • The fact that somebody can self-administer the treatment safely in their home allows not only  the patient a better quality of life in that they can stay in their own home, but also if a community Nurse or Carer is required to assist,  there is still a significant cost saving for the local authority.

The company’s key objective is to develop and CE Mark the minimal viable product for a hospital use of a proposed device for fluid overload management. The product when ready would be available for direct sales via a small sales team or through a global distribution network. 

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.